CANSINOBIO (06185) Initiates Phase I/II Clinical Trial for PCV24 with First Participant Enrolled

Stock News05-26

CANSINOBIO (06185) announced that the Phase I/II clinical trial for its 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/Tetanus Toxoid), PCV24, has officially commenced, with the first participant enrolled. The company's PCV24 received clinical trial approval from China's National Medical Products Administration (NMPA) in January 2026. This vaccine covers the major prevalent pneumococcal serotypes and utilizes a covalent conjugation method of polysaccharide antigens to protein carriers, along with a dual-carrier technology. It is intended for immunization of individuals aged 2 months (minimum 6 weeks) and older to prevent infections caused by 24 pneumococcal serotypes. The company's 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197/Tetanus Toxoid), marketed under the brand name Youpeixin®, received NMPA approval for its New Drug Application in June 2025. PCV24 represents a further expansion of the company's pneumococcal product portfolio. As of the date of this announcement, there are no commercially available 24-valent pneumococcal conjugate vaccines in any market globally. The Phase I/II clinical trial is designed to evaluate the safety and immunogenicity of PCV24 in individuals aged 2 months (minimum 6 weeks) and older.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1194186054?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-26 08:26","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194186054","market":"sh","top_or_hot":-1,"title":"CANSINOBIO (06185) Initiates Phase I/II Clinical Trial for PCV24 with First Participant Enrolled","media":"Stock News","content":"<p>CANSINOBIO (06185) announced that the Phase I/II clinical trial for its 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/Tetanus Toxoid), PCV24, has officially commenced, with the first participant enrolled. The company's PCV24 received clinical trial approval from China's National Medical Products Administration (NMPA) in January 2026. This vaccine covers the major prevalent pneumococcal serotypes and utilizes a covalent conjugation method of polysaccharide antigens to protein carriers, along with a dual-carrier technology. It is intended for immunization of individuals aged 2 months (minimum 6 weeks) and older to prevent infections caused by 24 pneumococcal serotypes. The company's 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197/Tetanus Toxoid), marketed under the brand name Youpeixin®, received NMPA approval for its New Drug Application in June 2025. PCV24 represents a further expansion of the company's pneumococcal product portfolio. As of the date of this announcement, there are no commercially available 24-valent pneumococcal conjugate vaccines in any market globally. The Phase I/II clinical trial is designed to evaluate the safety and immunogenicity of PCV24 in individuals aged 2 months (minimum 6 weeks) and older.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CANSINOBIO (06185) Initiates Phase I/II Clinical Trial for PCV24 with First Participant Enrolled</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCANSINOBIO (06185) Initiates Phase I/II Clinical Trial for PCV24 with First Participant Enrolled\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-05-26 08:26</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CANSINOBIO (06185) announced that the Phase I/II clinical trial for its 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/Tetanus Toxoid), PCV24, has officially commenced, with the first participant enrolled. The company's PCV24 received clinical trial approval from China's National Medical Products Administration (NMPA) in January 2026. This vaccine covers the major prevalent pneumococcal serotypes and utilizes a covalent conjugation method of polysaccharide antigens to protein carriers, along with a dual-carrier technology. It is intended for immunization of individuals aged 2 months (minimum 6 weeks) and older to prevent infections caused by 24 pneumococcal serotypes. The company's 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197/Tetanus Toxoid), marketed under the brand name Youpeixin®, received NMPA approval for its New Drug Application in June 2025. PCV24 represents a further expansion of the company's pneumococcal product portfolio. As of the date of this announcement, there are no commercially available 24-valent pneumococcal conjugate vaccines in any market globally. The Phase I/II clinical trial is designed to evaluate the safety and immunogenicity of PCV24 in individuals aged 2 months (minimum 6 weeks) and older.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1515","symbol_name":"抗疫概念","start_time":0,"source_url":"","article_id":"1194186054","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194186054","pubTimestamp":1779755182,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"CANSINOBIO (06185) announced that the Phase I/II clinical trial for its 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/Tetanus Toxoid), PCV24, has officially commenced, with the...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1515":"抗疫概念","BK1191":"制药","BK1161":"生物科技","06185":"康希诺生物","BK1574":"生物医药B类股"},"translate_title":"康希诺生物(06185)启动PCV24 I/II期临床试验，首名受试者入组","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06185":1},"content_text":"CANSINOBIO (06185) announced that the Phase I/II clinical trial for its 24-valent pneumococcal polysaccharide conjugate vaccine (CRM197/Tetanus Toxoid), PCV24, has officially commenced, with the first participant enrolled. The company's PCV24 received clinical trial approval from China's National Medical Products Administration (NMPA) in January 2026. This vaccine covers the major prevalent pneumococcal serotypes and utilizes a covalent conjugation method of polysaccharide antigens to protein carriers, along with a dual-carrier technology. It is intended for immunization of individuals aged 2 months (minimum 6 weeks) and older to prevent infections caused by 24 pneumococcal serotypes. The company's 13-valent pneumococcal polysaccharide conjugate vaccine (CRM197/Tetanus Toxoid), marketed under the brand name Youpeixin®, received NMPA approval for its New Drug Application in June 2025. PCV24 represents a further expansion of the company's pneumococcal product portfolio. As of the date of this announcement, there are no commercially available 24-valent pneumococcal conjugate vaccines in any market globally. The Phase I/II clinical trial is designed to evaluate the safety and immunogenicity of PCV24 in individuals aged 2 months (minimum 6 weeks) and older.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.43.1","shortVersion":"4.43.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1194186054","isCrawlerRequest":true}